Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PRME

Prime Medicine Inc

Mar 10 • 04:00PM ET

4.05

-0.06 -1.46 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT BEAM ALLO VERV DNLI IGMS PSTX SANA

| Held by: ARKG XBI VTI IWM VXF IWN IBB SCHA VTWO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.37	Insider Own	47.66%	Shs Outstand	180.51M	Perf Week	-4.26%
Market Cap	731.24M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	0.00%	Shs Float	94.50M	Perf Month	13.45%
Enterprise Value	669.99M	PEG	-	EPS next Q	-0.25	Inst Own	41.34%	Short Float	28.83%	Perf Quarter	8.29%
Income	-201.14M	P/S	157.94	EPS this Y	32.21%	Inst Trans	5.45%	Short Ratio	8.42	Perf Half Y	4.11%
Sales	4.63M	P/B	6.05	EPS next Y	10.73%	ROA	-36.35%	Short Interest	27.25M	Perf YTD	16.71%
Book/sh	0.67	P/C	4.12	EPS next 5Y	16.34%	ROE	-146.81%	52W High	6.94 -41.64%	Perf Year	94.71%
Cash/sh	0.98	P/FCF	-	EPS past 3/5Y	2.55% -91.28%	ROIC	-87.77%	52W Low	1.11 264.86%	Perf 3Y	-70.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -2.32%	Gross Margin	-58.05%	Volatility	9.21% 8.03%	Perf 5Y	-
Dividend TTM	-	EV/Sales	144.71	EPS Y/Y TTM	19.04%	Oper. Margin	-4498.06%	ATR (14)	0.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.84	Sales Y/Y TTM	55.28%	Profit Margin	-4342.44%	RSI (14)	53.21	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	4.84	EPS Q/Q	28.39%	SMA20	6.44%	Beta	2.60	Target Price	7.00
Payout	-	Debt/Eq	0.96	Sales Q/Q	-61.61%	SMA50	5.34%	Rel Volume	0.69	Prev Close	4.11
Employees	146	LT Debt/Eq	0.90	Earnings	Mar 03 BMO	SMA200	5.64%	Avg Volume	3.24M	Price	4.05
IPO	Oct 20, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.49% -34.60%	Trades		Volume	2,255,677	Change	-1.46%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Downgrade	Citigroup	Buy → Neutral	$1.50
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27
Nov-14-22	Initiated	Jefferies	Buy	$25
Nov-14-22	Initiated	Goldman	Neutral	$22

Show Previous Ratings

Mar-08-26 12:57PM	Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway (Insider Monkey)
Mar-03-26 09:15AM	Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -9.23%
08:00AM	Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-25-26 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.83%
Feb-11-26 05:15PM	Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Loading…
Jan-07-26 08:00AM	Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +9.19%
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
Dec-31-25 11:12AM	LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases (Insider Monkey)
Dec-30-25 11:45PM	Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data (Insider Monkey)
Dec-07-25 08:05AM	Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease (GlobeNewswire)
Nov-25-25 08:00AM	Prime Medicine to Present at 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-11-25 08:00AM	Prime Medicine to Present at Jefferies Global Healthcare Conference (GlobeNewswire) +11.21%
Nov-07-25 10:21AM	CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.85%
08:10AM	Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
08:01AM	Loading…
Nov-03-25 08:01AM	Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (GlobeNewswire) -7.69%
Oct-30-25 04:01PM	Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy (GlobeNewswire) +13.56%
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV) +9.88%
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 04:50PM	Why Cathie Wood is Loading Up on These 2 Growth Stocks (And Should You?) (Barchart) +16.46%
Aug-26-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 09:10AM	Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -9.58%
08:00AM	Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-25 04:01PM	Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.02% +11.39%
Jul-31-25 11:40PM	JonesTrading Maintains a Buy on Prime Medicine (PRME) (Insider Monkey)
Jul-30-25 09:33PM	Prime Medicine Announces Pricing of Public Offering (GlobeNewswire)
04:01PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:55AM	Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
12:35AM	Loading…
Jul-20-25 12:35AM	BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT (Insider Monkey)
Jul-16-25 08:10AM	Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy (Business Wire) -5.83%
07:00AM	Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis (GlobeNewswire)
Jul-07-25 12:48PM	Prime Medicine stock soars amid gene editing sector momentum (Investing.com) +22.19%
Jul-06-25 04:01AM	Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data (Insider Monkey)
May-29-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-25 02:24PM	Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty (Insider Monkey)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks) +5.58%
May-19-25 08:31AM	Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition (GlobeNewswire) -16.04%
08:30AM	Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease (GlobeNewswire)
08:28AM	Prime Medicine claims proof of concept, but lays off staff in pivot (BioPharma Dive)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.04%
08:00AM	Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-25 05:10PM	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.77%
May-05-25 08:25AM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.55%
Apr-25-25 10:51AM	Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 (Seeking Alpha)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -10.30%
Mar-20-25 06:48PM	Why Prime Medicine Stock Was Climbing Higher This Week (Motley Fool)
Mar-19-25 02:56PM	Why Prime Medicine Stock Is Soaring Today (Fool) +13.64%
Mar-18-25 08:09AM	Prime sets sights on liver, lung disease as next target for its gene editing tech (BioPharma Dive)
07:00AM	Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-25 08:00AM	Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 08:00AM	Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-25-24 04:10AM	Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio (Motley Fool)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks) +6.36% +6.64%
09:33AM	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target (MT Newswires)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-16-24 07:14AM	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target (MT Newswires)
May-14-24 09:55AM	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? (Zacks)
May-13-24 11:12AM	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating (MT Newswires) +14.44%
08:00AM	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-24 03:00AM	Alphabet Bought Up Two Slumping Stocks (Barrons.com)
May-10-24 02:23PM	Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments (GuruFocus.com)
01:53PM	PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-08-24 08:00AM	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
May-03-24 12:00PM	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock (Zacks)
May-01-24 08:00AM	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference (GlobeNewswire) +7.11%
Apr-30-24 06:01AM	Prime Medicine gets green light for trials of first-ever prime editing drug (Clinical Trials Arena)
Apr-29-24 10:12AM	Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance (MT Newswires) +9.83%
07:35AM	Prime gets FDA green light to begin first trial test of prime editing (BioPharma Dive)
07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GV 2021 GP, L.L.C.	10% Owner	Aug 01 '25	Buy	3.30	1,500,000	4,950,000	3,262,440	Aug 05 04:07 PM
NELSEN ROBERT	Director	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:19 PM
ARCH Venture Partners XII, LLC	10% Owner	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:19 PM
ARCH Venture Partners X, LLC	10% Owner	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:18 PM
Liu David R.	10% Owner	Jun 30 '25	Buy	2.52	21,000	52,830	20,240,945	Jul 01 04:03 PM
Liu David R.	10% Owner	Jun 23 '25	Buy	2.16	21,000	45,402	20,219,945	Jun 23 04:33 PM
Liu David R.	10% Owner	Jun 16 '25	Buy	1.49	21,000	31,196	20,198,945	Jun 16 05:14 PM
Liu David R.	10% Owner	Jun 11 '25	Buy	1.60	21,000	33,590	20,177,945	Jun 12 04:49 PM
Brudnick Richard	Chief Business Officer	May 20 '25	Buy	1.19	20,000	23,790	20,000	May 22 04:22 PM
LEE ANN L.	Chief Technical Officer	May 21 '25	Buy	1.13	100,000	113,000	100,000	May 22 04:21 PM
Reine Allan	Chief Executive Officer	May 21 '25	Buy	1.18	125,000	147,150	125,000	May 22 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRME

Prime Medicine Inc

Upgrade your FINVIZ experience